Mednet Logo
Community

Are you routinely using thrombopoietin agonists in patients with hep C and HCC?

If so, for what platelet count threshold and do you have a preference as to which agent?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Indiana University Melvin and Bren Simon Cancer Center
Answered on

Thrombocytopenia is a common issue in patients with advanced liver disease due to decreased thrombopoietin production and hypersplenism sequestration from portal hypertension. The degree of thrombocytopenia is often a maker of both severity of liver disease.

There are several TPO agonists on the mark...

Join for free or sign in to see the full answer